Arcus Biosciences, Inc. · NYSE:RCUS

Arcus Biosciences — Investor Presentation (January 2024)

58 slides from Arcus Biosciences's investor presentation, Jan 29, 2024

  1. Slide 1: Combining to Cure

    ® COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. CORPORATE PRESENTATION January 2024

  2. Slide 2: Forward-looking Statements/Safe Harbor

    Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. (“we,” “Arcus” or the “Company”) made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results

  3. Slide 3: Arcus Has Created a Late-stage Portfolio of Differentiated Assets

    Arcus Has Created a Late-stage Portfolio of Differentiated Assets, Fueled by a Highly Productive R&D Engine FUNDING INTO LATE-STAGE COMPANY MULTIPLE PHASE 3 2027 STUDIES FOR DOM IN Line of sight to first ~$1.2B in pro forma cash, product approval (dom/zim) LUNG & UPPER GI cash equivalents & marketab

  4. Slide 4: Gilead Equity Investment and Portfolio Prioritization Enables Funding of Multiple Phase 3 Programs

    Gilead Equity Investment and Portfolio Prioritization Enables Funding of Multiple Phase 3 Programs • $320mm investment at $21.00 per share EQUITY • Increases Gilead's ownership to 33%, further aligning the two companies INVESTMENT • Funds Arcus into 2027, through multiple late-stage datasets • Closu

  5. Slide 5: Broad Portfolio of Investigational Molecules with Best-in-Class Potential

    Arcus Has a Broad Portfolio of Investigational Molecules with Best- in-Class Potential Targeting Huge Market Opportunities DIFFERENTIATED ANTI-TIGIT + DIFFERENTIATED SMALL MOLECULES NEXT-GENERATION PROGRAMS ANTI-PD-1 BACKBONE AB521: Potential best-in-class HIF-2α AB801: Potential best-in-class domva

  6. Slide 6: Three Late-Stage Programs with Multiple Upcoming Milestones

    Three Late-Stage Programs with Multiple Upcoming Milestones; Earlier-Stage Portfolio Maturing Program Disease Study Line & Regimen Ph 1/1b Ph 2 Ph 3 Upcoming Milestones 1L, PD-L1 all-comers, metastatic • 2024: Enrollment completion dom + zim + chemo vs pembro + chemo Lung cancer PLANNED • YE2024 / E

  7. Slide 7: Our Partnerships Greatly Expand & Accelerate Opportunities

    Our Partnerships Greatly Expand & Accelerate Opportunities Inherent in Arcus’s Portfolio 10-YEAR “ALL-IN” COLLABORATION • Over $1.7b in non-dilutive payments and equity investments from Gilead • Gilead has opted into 5 molecules to date -- shares costs for studies within the joint development plan •

  8. Slide 8: Domvanalimab in Non-Small Cell Lung Cancer and Upper GI Cancers

    Domvanalimab in Non-Small Cell Lung Cancer and Upper GI Cancers 8 © Arcus Biosciences 2024

  9. Slide 9: Domvanalimab, an Fc-Silent anti-TIGIT

    Domvanalimab, an Fc-Silent anti-TIGIT Dom may have important DOMVANALIMAB differences over Fc-enabled Most clinically advanced Fc-silent anti-TIGIT antibody in development anti-TIGIT competitors ZIMBERELIMAB ✓ Peripheral Treg numbers do not decrease with dom + zim, but they do Anti-PD-1 antibody; ap

  10. Slide 10: Two De-Risking Phase 2 Datasets for Domvanalimab Regimens Presented in 2023

    Two De-Risking Phase 2 Datasets for Domvanalimab-Containing Regimens Were Presented in 2023 1L Gastric/EAC/GEJ 1L PD-L1 high NSCLC dom + zim + FOLFOX (n=40) dom + zim vs. zim vs. etruma + dom + zim (n=150) • PD-L1-high (TAP ≥5%) for DZ + FOLFOX*: • PFS HRs: − ORR/cORR: 80% / 73% − 0.67 for DZ vs. Z

  11. Slide 11: Phase 3 Program for Dom is Targeting Significant Market Opportunities

    Phase 3 Program for Dom is Targeting Significant Market Opportunities STUDY LEAD SPONSOR SETTING US PATIENT POPULATION1 1L NSCLC, PD-L1 All comers 119k patients NSCLC TBA Stage 3 NSCLC 21k patients 1L Gastric/GEJ/EAC 25k patients $10B+ addressable Multi-billion revenue opportunities for Arcus / Gile

  12. Slide 12: Summary of EDGE-Gastric Arm-A1 Results and Domvanalimab Clinical Program in Upper GI Cancers

    Summary of EDGE-Gastric Arm-A1 Results and Domvanalimab Clinical Program in Upper GI Cancers Data presented at the November 2023 ASCO Plenary Series, based on data cut off of September 4, 2023. 12 © Arcus Biosciences 2024

  13. Slide 13: Phase 2 Trial to Evaluate Dom- and Zim-based combos in Advanced Upper GI Malignancies

    Phase 2 Trial to Evaluate Dom- and Zim-based combos in Advanced Upper GI Malignancies ARMS NOT RANDOMIZED, ENROLLED SEQUENTIALLY ARM A1: COHORT A dom + zim Q4W + FOLFOX Q2W 1L N ≈ 40 per arm ARM A2: zim Q4W + FOLFOX Q2W KEY ELIGIBILITY CRITERIA PRIMARY ENDPOINTS: • Locally advanced • Safety unresect

  14. Slide 14: Results for Arm A1 in 1L Metastatic Gastric/GEJ/EAC Presented at ASCO Plenary

    Results for Arm A1 in 1L Metastatic Gastric/GEJ/EAC Were Presented at ASCO Plenary in November 2024 KEY ELIGIBILITY CRITERIA • First-line locally advanced PRIMARY ENDPOINTS: unresectable or metastatic gastric/GEJ/EAC • Safety • Investigator ORR • Measurable disease per dom 1600 mg Q4W N ≈ 40 RECIST

  15. Slide 15: Promising ORR and 6-Month PFS Results

    Promising ORR and 6-Month PFS Results • As of the 4 September 2023 data cutoff, 24 patients (59%) continued on study treatment PD-L1 High* PD-L1 Low* Efficacy-Evaluable (TAP ≥5%) (TAP <5%) N=41 N=15 N=24 n (%) n (%) n (%) ORR, % [95% CI] 80 [52, 96] 46 [26, 67] 59 [42, 74] Confirmed ORR, % [95% CI]

  16. Slide 16: Almost All Patients Experience Some Benefit, Irrespective of PD-L1 Status

    Almost All Patients Experience Some Benefit, Irrespective of PD-L1 Status * *MSI-high TAP: tumor area positiv ity 16 Janjigian et al. ASCO Plenary Series, Nov . 7, 2023; data cut of f of Sept. 4, 2023 © Arcus Biosciences 2024

  17. Slide 17: Landmark 6-Month PFS Compares Favorably to Benchmark Data

    Landmark 6-Month PFS Compares Favorably to Benchmark Data of 60-65%; Median PFS Still Immature Efficacy-Evaluable (N=41) PD-L1 High (TAP ≥5%, N=15) 6-month PFS = 77% 6-month PFS = 93% Median, months Month 6 Rate, % Median Follow-up Median, months Month 6 Rate, % Median Follow-up Events, n (%) Events

  18. Slide 18: Safety Profile is Similar to FOLFOX Alone

    Safety Profile is Similar to FOLFOX Alone Arm A1 TEAE N=41, n (% ) 70 Any Grade TEAEs ≥20% Any TEAE 41 (100) Grade 1-2 60 Grade ≥3 TEAEs related to any study 40 (98) drug 50 Grade ≥3 TEAEs 28 (68) Patients, % 40 Grade ≥3 TEAEs related to any 49 23 (56) study drug 30 54 2 2 2 Serious TEAEs 10 (24) 5

  19. Slide 19: Phase 3 Evaluating Dom + Zim + Chemo vs Nivo + Chemo in 1L Gastric

    Phase 3 Evaluating Dom + Zim + Chemo vs Nivo + Chemo in 1L Gastric, GEJ and Esophageal Adenocarcinoma KEY ELIGIBILITY N=970 CRITERIA: • 1L locally advanced DUAL PRIMARY ENDPOINTS: unresectable or domvanalimab + zimberelimab + PI • OS ITT metastatic w/o prior choice of chemo* • OS in TAP ≥5% systemic

  20. Slide 20: Summary of ARC-7 Results and Domvanalimab Clinical Program in NSCLC

    Summary of ARC-7 Results and Domvanalimab Clinical Program in Non-Small Cell Lung Cancer Data presented at the 2023 ASCO Annual Meeting, based on data cut off of Feb. 7, 2023. 20 © Arcus Biosciences 2024

  21. Slide 21: Randomized, Open-label, Ph2 Study in First-Line, Metastatic, PD-L1-High NSCLC

    Randomized, Open-label, Ph2 Study in First-Line, Metastatic, PD-L1-High NSCLC ARM 1 STAGE IV NSCLC zim (Z) 360 mg IV Q3W KEY ELIGIBILITY: CO-PRIMARY ENDPOINTS • Treatment-naïve for • Investigator-assessed ORR & metastatic disease ARM 2 PFS per RECIST v1.1 R dom + zim (DZ) • PD-L1 ≥50%, locally 1:1:1

  22. Slide 22: Dom-containing Arms Improved ORRs vs Zim Monotherapy

    Dom-containing Arms Improved ORRs vs Zim Monotherapy • Across all arms, one patient in the DZ arm had a pending partial response that was confirmed after data cut-off date • Subjects ongoing treatment with stable disease have potential to contribute to objective response rate with further data matur

  23. Slide 23: Addition of Dom to Zim Resulted in a 33% Reduction in Risk of Progression

    Addition of Dom to Zim Resulted in a 33% Reduction in Risk of Progression or Death, Compared to Zim Monotherapy CI: conf idence interv al; D/dom: domv analimab; HR: hazard ratio; NE: not ev aluable; PFS: progression- f ree surv iv al; Z/zim: zimberelimab 23 Johnson et al. Abstract 397600, ASCO 2023;

  24. Slide 24: Overall Safety Profile

    Overall Safety Profile ARM 1 (Z) ARM 2 (DZ) ARM 3 (EDZ) ITT, % (n) (n=50) (n=50) (n=50) Any TEAEs 100% (50) 98% (49) 98% (49) Grade ≥3 TEAE 64% (32) 46% (23) 60% (30) Grade 5, Related to Study Treatment* 2% (1) 2% (1) 4% (2) Serious TEAE 56% (28) 34% (17) 52% (26) TEAEs leading to study drug 28% (14

  25. Slide 25: Phase 3 Evaluating Dom + Zim + Chemo vs. Pembro + Chemo in 1L NSCLC

    Phase 3 Evaluating Dom + Zim + Chemo vs. Pembro + Chemo in 1L NSCLC (All PD-L1 Subgroups) • Uses standard of care, pembrolizumab, in the comparator arm ELIGIBILITY CRITERIA: ARM A ENDPOINTS: • Metastatic NSCLC without dom + zim + platinum doublet PRIMARY actionable mutations (ARM A vs B) • No prior

  26. Slide 26: Phase 3 Evaluating Dom + Durva vs Placebo + Durva in Stage III NSCLC

    Phase 3 Evaluating Dom + Durva vs Placebo + Durva in Unresectable, Stage III NSCLC • Combines domvanalimab (dom) with durvalumab (durva) standard-of-care in Stage III NSCLC • Potential to be first anti-TIGIT combination in this curative intent setting PATIENT POPULATION: ARM A (N=430) • Patients wit

  27. Slide 27: CD73-Adenosine Axis Programs

    CD73-Adenosine Axis Programs 27 © Arcus Biosciences 2024

  28. Slide 28: Quemliclustat in Pancreatic Cancer

    Quemliclustat in Pancreatic Cancer 28 © Arcus Biosciences 2024

  29. Slide 29: Quemliclustat: A Unique, Highly Potent and Selective Small Molecule CD73 Inhibitor

    Quemliclustat (quemli): A Unique, Highly Potent and Selective Small Molecule CD73 Inhibitor with Several Key Advantages QUEMLICLUSTAT • Highly potent molecule Potential advantages over • Target coverage achieved at doses CD73 antibodies1 as low as 25 mg every two weeks • Extremely long (4+ days) hal

  30. Slide 30: Final Overall Survival Analysis for Quemli in Pancreatic Cancer (ARC-8)

    Final Overall Suvival Analysis for Quemli in Pancreatic Cancer (ARC-8) Data presented at ASCO GI, January 19, 2024, based on a data cutoff of June 19, 2023. 30 © Arcus Biosciences 2024

  31. Slide 31: Highlights from the ARC-8 Study in 1L PDAC

    Highlights from the ARC-8 Study in 1L PDAC Median overall survival (mOS) was 15.7 months for patients treated with a quemliclustat- based regimen, which exceeds the historical benchmark data for chemotherapy alone (8.5 – 11.7 months)1,2 A 37% reduction in risk of death and a 5.9-month improvement in

  32. Slide 32: ARC-8 Study Design Included Dose Escalation, Expansion and Randomized Portions

    ARC-8 Study Design Included Dose Escalation, Expansion and Randomized Portions RANDOMIZATION DOSE ESCALATION DOSE EXPANSION (WITH AND WITHOUT ZIM) 125 mg quemli IV Q2W + G/nP + zim (n=3-6) COHORT A1 100 mg QZ + G/nP (n=61) COHORT A 100 mg quemli IV Q2W R 1L mPDAC + G/nP + zim (n=6) RDE 100 mg QZ + G

  33. Slide 33: Dataset Includes Four Groups of Patients Treated with 100 mg of Quemli

    Dataset Includes Four Groups of Patients Treated with 100 mg of Quemli Quemli Cohort Combination Participants Dosed >18m OS f/u? Population Dose Dose escalation 25 mg Q + Z + G/nP (quad) 4 Yes 1L mPDAC Dose escalation 50 mg Q + Z + G/nP (quad) 6 Yes 1L mPDAC Dose escalation 75 mg Q + Z + G/nP (quad)

  34. Slide 34: Demographics And Baseline Characteristics Are Well Balanced Across Arms

    Demographics And Baseline Characteristics Are Well Balanced Across Arms & Efficacy-evaluated Populations % ECOG 1 (65%-69%) Was Higher than Historical G/nP Studies (42-57%); % Liver Mets (59%-69%) Was Slightly Lower than Historical G/nP Studies (78-85%) – See Slide 36 for OS Results A2: Q + G/nP A1:

  35. Slide 35: With 21-month Median Follow-up, OS Results Exceed Ph3 Benchmarks for G/nP

    With 21-month Median Follow-up, OS Results Exceed Ph3 Benchmarks for G/nP Phase 3 G/nP median OS G/nP Benchmarks1,2 Benchmark Median OS 8.5 – 11.1 months CI: conf idence interv al; G/nP: gemcitabine/nab-paclitaxel; Ph3: Phase 3 1. Abraxane USPI, 2020 and Wainberg ZA, Melisi D, Macarulla T, et al. NA

  36. Slide 36: Favorable OS for Patients With & Without Liver Metastasis

    Favorable OS for Patients With & Without Liver Metastasis • Because ARC-8 had a lower incidence of liver mets than historical studies, we analyzed the OS for ARC-8 patients with and without liver mets as shown below • When adjusting for the lower incidence of liver mets in the triplet arm, mOS for t

  37. Slide 37: Safety Profile Similar to G/nP with Regards to Overall TEAEs

    Safety Profile Similar to G/nP with Regards to Overall TEAEs NAPOLI-3 G/nP A2: Q + G/nP Pooled Q100 QZ + G/nP All Pooled Q100 Q % Benchmark4 (n=29) (n=93) ±Z)+G/nP (n=122) (n=379) Any TEAE 100 100 100 99 Any TRAE 100 98.9 99.2 93 Grade 3-5 TEAE 89.7 83.9 85.2 86 Grade 3-5 TRAE 75.9 72.0 73.0 68 Seri

  38. Slide 38: Arcus & Medidata AI Synthetic Control Arm Project

    Arcus & Medidata AI Synthetic Control Arm (SCA) Project • Developed in collaboration with Medidata, the industry’s leading provider of electronic data capture for clinical trials • Constructed SCA using historical data from patients treated with G/nP alone and balanced to the patient baseline charac

  39. Slide 39: Quemli-based Regimen Significantly Reduced Risk of Death by 37%

    Quemli-based Regimen Significantly Reduced Risk of Death by 37% and increased mOS by 5.9 months CI: conf idence interv al; mOS: median ov erall surv iv al; quemli: quemliclustat 39 Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut of f of June 19, 2023 © Arcus Biosciences 2024

  40. Slide 40: Etrumadenant in Colorectal Cancer

    Etrumadenant in Colorectal Cancer 40 © Arcus Biosciences 2024

  41. Slide 41: Etrumadenant Represents a Potentially Best-in-Class Adenosine Receptor Antagonist

    Etrumadenant Represents a Potentially Best-in-Class Adenosine Receptor Antagonist ETRUMADENANT Etruma has ideal • Highly potent small molecule that pharmacological properties inhibits both the A2aR and A2bR receptors ✓ Retains potency in physiologically • Excellent penetration of tumor tissue releva

  42. Slide 42: Randomized Phase 2 Study to Evaluate Etruma Combinations in 3L+ mCRC

    Randomized Phase 2 Study to Evaluate Etruma Combinations in 3L+ mCRC • Randomized Phase 2 study evaluating etruma + zim + chemo combinations vs. SOC in 2L/3L mCRC • Mature PFS / OS data for Cohort B (3L) expected to be presented in 1H24 (n=105) • Cohort A (2L) results are still immature etruma + zim

  43. Slide 43: HIF-2α Program

    HIF-2α Program 43 © Arcus Biosciences 2024

  44. Slide 44: Value Proposition for AB521, a Potential Best-in-Class HIF-2α Inhibitor

    Value Proposition for AB521, a Potential Best-in-Class, HIF- 2α Inhibitor Potency Novel Combinations Opportunity to reach greater intra- Opportunity to create potentially best- tumoral HIF-2α inhibition compared in-class and first-in-class to 120 mg dose of belzutifan combinations • Requires a compo

  45. Slide 45: Extensive Preclinical Characterization Confirms Greater Potency of AB521

    Extensive Preclinical Characterization Confirms Greater Potency of AB521 Relative to that of Belzutifan (MK-6482) ASSAY AB521 MK-6482a HIF-2α 786-O Luc Reporter 8.2 ± 2.5 (n=24) 16.9 ± 10.1 (n=8) IC50 (nM) CELLULAR Control 786-O Luc Reporter > 10,000 (n=6) > 10,000 (n=7) IC50 (nM) HIF-2α 786-O Luc R

  46. Slide 46: AB521 is a HIF-2α Inhibitor with Best-in-Class PK-PD Properties

    AB521 is a HIF-2α Inhibitor with Best-in-Class PK-PD Properties 20 mg of AB521 achieves near-complete EPO Human PK profile of AB521 Increases in a suppression (peripheral PD marker for HIF2α inhibition) - dose-linear fashion while a 120mg dose of belzutifan (the approved dose) is Daily 100 mg AB521

  47. Slide 47: AB521 Monotherapy Dose Escalation/Expansion in ccRCC is Ongoing

    AB521 Monotherapy Dose Escalation/Expansion in ccRCC is Ongoing PH 1 DOSE ESCALATION 3+3 design with 21-day DLT window Solid-tumor patients w/o SOC KEY INCLUSION CRITERIA • At least 1 measurable lesion per Flexible RECIST 1.1 language for • Adequate organ and marrow intermediate AB521 up to 200 mg Q

  48. Slide 48: Phase 1b/2 Study of AB521 + Zanzalintinib +/- Nivolumab

    Phase 1b/2 Study of AB521 + Zanzalintinib +/- Nivolumab in Advanced Solid Tumors Including ccRCC* DOSE FINDING DOSE EXPANSION * Potential multiple additional cohorts of ~6 patients each, guided by BOIN DLT rules Zana + AB521 RD+1 COHORT A Zanza 100 mg COHORT 1 Zanza RD + STELLAR-009 KEY STUDY OBJECT

  49. Slide 49: AXL Program

    AXL Program 49 © Arcus Biosciences 2024

  50. Slide 50: AXL Signaling is a Common Mechanism of Resistance to Chemotherapy and Immunotherapy

    AXL Signaling is a Common Mechanism of Resistance to Chemotherapy and Immunotherapy in Tumors AXL signals via Ligand-dependent and Ligand-independent mechanisms THERAPEUTIC HYPOTHESIS: AXL inhibition will overcome multiple mechanisms of drug-resistance MERTK EGFR TYRO3 VEGFR HER2 AB801 sensitizes ca

  51. Slide 51: AB801 is a Potent, Selective, and Efficacious AXL Inhibitor

    AB801 is a Potent, Selective, and Efficacious AXL Inhibitor Combination of AB801 with Oxaliplatin & α-PD-1 AB801 is a highly potent Increases Anti-Tumor Efficacy and Survival and selective AXL inhibitor in Preclinical Models* Assay AB801 AXL Ki 0.024 nM 3000 Oxaliplatin Stopped 100 Stopped Treatment

  52. Slide 52: AB801 is Believed to be the Most Potent & Selective AXL Inhibitor in Clinical Development

    AB801 is Believed to be the Most Potent & Selective AXL Inhibitor in Clinical Development THERAPEUTIC HYPOTHESIS: Inhibiting AXL will overcome resistance against chemotherapy and immunotherapy in human tumors • AB801 was designed to potently and selectively inhibit AXL signaling in tumors, resulting

  53. Slide 53: Appendix

    APPENDIX 53 © Arcus Biosciences 2024

  54. Slide 54: Domvanalimab: Most Advanced Fc-Silent TIGIT Antibody in Clinical Development

    Domvanalimab (dom): Most Advanced Fc-Silent TIGIT Antibody in Clinical Development IMMUNOSUPPRESSION IMMUNE CELL ACTIVATION & TUMOR CELL KILLING T or NK cell T or NK cell PD-1 TIGIT TIGIT Zimberelimab PD-1 CD226 Cytotoxic CD226 proteins PD-L1 released CD155 domvanalimab PD-L1 CD155 Tumor cell Tumor

  55. Slide 55: AB521 in the Cancer Cell Nucleus

    AB521 in the Cancer Cell Nucleus 1 3 In many cancers, the transcription factor HIF-2α is AB521 AB521 binds to HIF-2α The highly specific small dysregulated, allowing it to molecule AB521 can translocate freely to the penetrate cells and bind cancer cell nucleus. HIF-2α. HIF-2α HIF-1β 4 AB521 inhibit

  56. Slide 56: The CD73-Adenosine Axis Plays a Critical Role in Suppression of the Immune Response

    The CD73-Adenosine Axis Plays a Well-Established and Critical Role in Suppression of the Immune Response NK Cells ATP ↓ cytotoxicity etrumadenant blocks adenosine from binding to A2aR and A2bR, 1 ATP is released from blocking immunosuppression A2a tumor cells in A2b Receptor response to cellular Rec

  57. Slide 57: Platform Design to Rapidly Evaluate Novel Combinations for NSCLC

    Platform Design to Rapidly Evaluate Novel Combinations for NSCLC, Including Quemli and Dom-based Regimens PRELIMINARY STAGE EXPANSION PRE-SCREENING SCREENING (N=20/30) STAGE PRIMARY ENDPOINTS • ORR • Safety and tolerability EXPERIMENTAL SUB-STUDY A TREATMENT ARMS Treatment arm(s) SECONDARY 1L, metas

  58. Slide 58: Combining to Cure

    RCUS BIOSCIENCES COMBINING TO CURE”

Arcus Biosciences — Investor Presentation (January 2024) on 6ix